Zhonghua zheng xing shao shang wai ke za zhi = Zhonghua zheng xing shao shang waikf [i.e. waike] zazhi = Chinese journal of plastic surgery and burns · 1999
[Effects of intralesional injection of kenalog or interferon alpha-2b on PDGF BB gene expression in situ of hypertrophic scars].
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu S, Bao W, Yang X
Аннотация
OBJECTIVE: The study is to determine whether kenalog or interferon alpha-2b inhibits fibroblast growth in hypertrophic scars through decreasing PDGF.
METHOD: Six patients with hypertrophic scars received intralesional injection of kenalog or interferon alpha-2b. On the 3rd and 7th day after injection, scar samples from each patient were collected and PDGF mRNA expressions in situ were studied.
RESULTS: 1. On the 7th day after intralesional injection of kenalog or interferon alpha-2b, expressions of PDGF BB mRNAs decreased significantly (P < 0.01). However, on the 3rd day the expressions of PDGF BB mRNAs of the intralesional-injected area and non-injected area were not significantly different (P > 0.05). 2. Gene expressions of PDGF BB in situ were higher in hypertrophic scars than in normal skin.
CONCLUSION: The mechanism of kenalog or interferon alpha-2b in ameliorating hypertrophic scar is to reduce mitosis and prohibit proliferation of fibroblasts in hypertrophic scars by inhibiting PDGF gene expression.
METHOD: Six patients with hypertrophic scars received intralesional injection of kenalog or interferon alpha-2b. On the 3rd and 7th day after injection, scar samples from each patient were collected and PDGF mRNA expressions in situ were studied.
RESULTS: 1. On the 7th day after intralesional injection of kenalog or interferon alpha-2b, expressions of PDGF BB mRNAs decreased significantly (P < 0.01). However, on the 3rd day the expressions of PDGF BB mRNAs of the intralesional-injected area and non-injected area were not significantly different (P > 0.05). 2. Gene expressions of PDGF BB in situ were higher in hypertrophic scars than in normal skin.
CONCLUSION: The mechanism of kenalog or interferon alpha-2b in ameliorating hypertrophic scar is to reduce mitosis and prohibit proliferation of fibroblasts in hypertrophic scars by inhibiting PDGF gene expression.